Coherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz

Coherus BioSciences Inc.'s (CHRS) 351(k) Biologics License Application for CHS-1701, a proposed biosimilar to Amgen's (AMGN) blockbuster Neulasta, has been accepted for review by the FDA.

from RTT - Biotech http://ift.tt/2dXaAIo
via IFTTT